Loading...

CVM CEL SCI CORP Product Launches 8-K Filing

CL S

CVM

CEL SCI CORP

(CVM)

2024 8-K

Show Summary

Show Summary

Equity Offerings

Management Change

Leadership Appointment

Placement Agency Agreement

Positive Results from Bias ...

Conference Presentation

Appointment of Mario Gobbo ...

Annual Meeting Results

Entry into Material Definit...

Entry into Material Definit...

Extension of Employment Agr...

Extension of Employment Agr...

Equity Offerings

Equity Offerings

Filing Letter with Quantita...

Underwriting Agreement

External Links:

CEL-SCI Corporation has appointed Dr. Nabil F. Saba as the lead for their upcoming Phase III clinical trial for Multikine in head and neck cancer, leveraging his extensive expertise in the field.

AI Assistant

CEL SCI CORP

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.